Skip to main content
SpringerLink
Log in

Interaction of [3H] estradiol — and [3H] monohydroxytamoxifen-estrogen receptor complexes with a monoclonal antibody

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

The aim of this study was to compare and contrast the interaction of estrogen ([3H]17β-estradiol)— or antiestrogen ([3H]monohydroxytamoxifen)—receptor complexes from human breast tumor cytosols with monoclonal antibodies raised to the human breast tumor estrogen receptor. Breast tumor cytosols containing estrogen receptor which sedimented as radiolabeled peaks in either the 8S, 8S and 4S, or 4S regions of sucrose density gradients, interacted with the monoclonal antibody D547 to produce a broad 9-10S peak, a broad 8S-10S peak, or a more discrete 8S peak, respectively. On high salt (0.4M KCl) sucrose density gradients the 4S ligand-receptor complex plus antibody produced a binding peak at approximately the 8S region of the gradient. These sedimentation studies with the monoclonal antibody D547, and similar studies with the monoclonal antibody D58, could detect no differences in the cytosolic estrogen receptor whether complexed with [3H]estradiol or with [3H]monohydroxytamoxifen. These observations were confirmed by Scatchard equilibrium saturation analysis and sucrose density gradient analysis of cytosols from the MCF-7 human breast cancer cell line. The antibody D547 interacted with 8S ER from these cytosols to produce a broad 8S-10S peak, but the antibody produced no change in the affinity or number of binding sites present in these cytosols. It seems, therefore, that the antigenic determinants recognized by these particular antibodies on the breast tumor cytosolic receptor are not significantly altered by the binding of either an estrogen or an antiestrogen to the receptor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abbreviations

ER:

estrogen receptor

E2 :

17β-estradiol

MHT:

monohydroxytamoxifen (l-[4-(2-dimethylaminoethoxy)phenyl]-l-(4-hydroxyphenyl)-2-phenylbutl-ene)

DHT:

5 α-dihydrotestosterone

DES:

diethylstilbestrol

R5020:

(17,21-dimethyl[-19-nor-4,9-pregnadiene-3,20-dione])

SDG:

sucrose density gradient

DCC:

dextran-coated charcoal

References

  1. Legha SS, Carter SK: Antiestrogens in the treatment of breast cancer. Cancer Treat Rev 3:205–216, 1976

    PubMed  Google Scholar 

  2. Sutherland RL, Jordan VC: Non-Steroidal Antioestrogens, Academic Press, Sydney, 1981

    Google Scholar 

  3. Jordan VC, Prestwich G: Binding of [3H]tamoxifen in the rat uterine cytosols: a comparison of swinging bucket and vertical tube rotor sucrose density gradient analysis. Mol Cell Endocrinol 8:179–188, 1977

    PubMed  Google Scholar 

  4. Capony F, Rochefort H: High affinity binding of the antiestrogen [3H]tamoxifen to the 8S estradiol receptor. Mol Cell Endocrinol 11:181–198, 1978

    PubMed  Google Scholar 

  5. Jordan VC, Collins MM, Rowsby L, Prestwich G: A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75:305–316, 1977

    PubMed  Google Scholar 

  6. Coezy E, Borgna JL, Rochefort H: Tamoxifen and metabolites in MCF-7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 42:317–323, 1982

    Google Scholar 

  7. Jordan VC, Allen KE: Evaluation of the antitumour activity of the nonsteroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16:239–251, 1980

    PubMed  Google Scholar 

  8. Borgna JL, Rochefort H: High affinity binding to the estrogen receptor of [3H]4-hydroxytamoxifen, an active antiestrogenic metabolite. Mol Cell Endocrinol 20:71–85, 1980

    PubMed  Google Scholar 

  9. Jordan VC, Fischer AM, Rose DP: Binding of [3H]monohydroxytamoxifen in human breast carcinoma cytosols. Eur J Cancer 17:121–122, 1981

    PubMed  Google Scholar 

  10. Jordan VC: Hydroxylated antioestrogens: New pharmacological probes to investigate oestrogen and antioestrogen action.In MK Agarwal (ed). Hormone Antagonists. Walter De Gruyter, Berlin, 1982, pp 109–128

    Google Scholar 

  11. Katzenellenbogen BS, Pavlik EJ, Robertson DW, Katzenellenbogen JA: Interaction of high affinity antiestrogen (α-[4-pyrrolidinoethoxy]phenyl-4-hydroxy-α1-nitrosostilbene, CI 628M) with uterine estrogen receptor. J Biol Chem 256:2908–2915, 1981

    PubMed  Google Scholar 

  12. Rochefort H, Borgna JL: Differences between oestrogen receptor activation by oestrogen and antioestrogen. Nature 292:257–259, 1981

    PubMed  Google Scholar 

  13. Eckert RL, Katzenellenbogen BS: Physical properties of estrogen receptor complexes in MCF-7 human breast cancer cells. J Biol Chem 257:8840–8846, 1982

    PubMed  Google Scholar 

  14. Greene GL, Fitch FW, Jensen EV: Monoclonal antibodies to estrophilin: probes for the study of estrogen receptors. Proc Natl Acad Sci USA 77:157–161, 1980

    PubMed  Google Scholar 

  15. Greene GL, Jensen EV: Monoclonal antibodies as probes for estrogen receptor detection and characterization. J Steroid Biochem 16:353–349, 1982

    PubMed  Google Scholar 

  16. Bradford M: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 72:248–254, 1976

    PubMed  Google Scholar 

  17. Geschwendt M, Hamilton TH: The transformation of the cytoplasmic oestradiol-receptor complex into the nuclear complex in a uterine cell-free system. Biochem J 128:611–616, 1972

    PubMed  Google Scholar 

  18. Scatchard G: The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51:660–672, 1949

    Google Scholar 

  19. Jordan VC, Tate AC: The antiestrogenic ligand. The Ligand Review 3(1):32–39, 1981

    Google Scholar 

  20. Jordan VC, Bowser-Finn RA: Binding of [3H]monohydroxytamoxifen by immature rat tissues in vivo. Endocrinology 110:1281–1291, 1982

    PubMed  Google Scholar 

  21. Fromson JM, Pearson S, Bramah S: The metabolism of tamoxifen (ICI 46,474). Part IIn Laboratory Animals. Xenobiotica 3:693–709, 1973

    PubMed  Google Scholar 

  22. Garcia M, Greene GL, Rochefort H, Jensen EV: Effect of antibodies to estrogen receptor on the binding of [3H]labeled antiestrogens and androstanediol in the uterus. Endocrinology 110:1355–1361, 1982

    PubMed  Google Scholar 

  23. Sutherland RL, Murphy LC, Foo MS, Green MD, Whybourne AM, Krozowski ZS: High-affinity anti-oestrogen binding site distinct from the oestrogen receptor. Nature 288:273–275, 1980

    PubMed  Google Scholar 

  24. Sutherland RL, Murphy LC: The binding of tamoxifen to human mammary carcinoma cytosol. Eur J Cancer 16:1141–1148, 1980

    PubMed  Google Scholar 

  25. Murphy LC, Sutherland RL: Modifications in the amino ether side chain of clomiphene influence affinity for a specific antioestrogen binding site in MCF-7 cell cytosol. Biochem Biophys Res Commun 100:1353–1360, 1981

    PubMed  Google Scholar 

  26. Rochefort H, Borgna JL, Coezy E, Vignon F, Westley B: Mechanism of action of tamoxifen and metabolites in MCF-7 human breast cancer cells.In RL Sutherland, VC Jordan (eds). Nonsteroidal Antioestrogens. Academic Press, Sydney, 1981, pp 355–364

    Google Scholar 

  27. Kon OL: An antiestrogen-binding protein in human tissues. J Biol Chem 258:3173–3177, 1983

    PubMed  Google Scholar 

  28. Sudo K, Monsma FJ, Katzenellenbogen BS: Antiestrogenbinding sites distinct from the estrogen receptor: subcellular localisation, ligand specificity and distribution in tissues of the rat. Endocrinology 112:425–434, 1983

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Human Oncology, Wisconsin Clinical Cancer Center, University of Wisconsin, 53792, Madison, WI, USA

    Anna C. Tate & V. Craig Jordan

  2. Ben May Laboratory for Cancer Research, University of Chicago, Illinois, USA

    Eugene R. DeSombre, Geoffrey L. Greene & Elwood V. Jensen

Authors
  1. Anna C. Tate
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eugene R. DeSombre
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Geoffrey L. Greene
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elwood V. Jensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. Craig Jordan
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Address for reprints: Dr V. Craig Jordan, Department of Human Oncology, Wisconsin Clinical Cancer Center, 600 Highland Avenue, Madison, WI 53792, USA

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tate, A.C., DeSombre, E.R., Greene, G.L. et al. Interaction of [3H] estradiol — and [3H] monohydroxytamoxifen-estrogen receptor complexes with a monoclonal antibody. Breast Cancer Res Tr 3, 267–277 (1983). https://doi.org/10.1007/BF01806700

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01806700

Keywords

Search

Navigation